医学
狼牙棒
心脏病学
冠状动脉疾病
内科学
狭窄
人口
心脏成像
放射科
队列
计算机断层血管造影
临床终点
自然史
肾脏疾病
冠状动脉钙
血管造影
冠状动脉粥样硬化
糖尿病
易损斑块
无症状的
前瞻性队列研究
队列研究
冠状动脉钙评分
射血分数
试验预测值
自然史研究
作者
Jairo Aldana-Bitar,Srikanth Krishnan,Keishi Ichikawa,April Kinninger,Logan C Hubbard,Tamer Sallam,Sion Roy,Suvasini Lakshmanan,Matthew Jay Budoff,Ronald P. Karlsberg
标识
DOI:10.1016/j.jcct.2026.05.002
摘要
Background Coronary artery disease (CAD) progression has been examined mainly in cohorts enriched for major adverse cardiovascular events (MACE), a high burden of traditional risk factors, or prior exposure to risk-modifying therapies. In contrast, plaque progression is poorly described in patients without prior MACE and receiving no anti-atherosclerotic treatment who undergo cardiac computed tomography angiography (CCTA) for clinical indications. We therefore investigated atherosclerosis progression in this understudied population using serial CCTA. Methods The NATURE-CT study retrospectively identified 205 participants from two outpatient cardiovascular imaging centers in Los Angeles. Eligible participants had ≥ two clinically indicated CCTAs at least 24 months apart, had a baseline coronary artery calcium score (CAC) ≤ 100, and experienced no interim MACE. Use of lipid-lowering or other anti-atherosclerotic medications was absent between scans. Individuals with diabetes mellitus, familial hypercholesterolemia, or chronic kidney disease were excluded. Plaque volume and luminal stenosis on each scan were quantified with a validated artificial-intelligence quantitative CT platform (AI-QCT; Cleerly Labs). The primary endpoint was the annualized change in total plaque volume (mm 3 per year). Results The cohort had a mean age of 54.9 ± 10.2 years and 72% were White men; 24 % had hypertension, 28 % dyslipidemia, and 15 % were current or former smokers. Mean baseline LDL was 111.6 ± 32.0 mg/dL. The median time between CCTA scans was 4.9 ± 2.2 years. At baseline, 54% had a CAC = 0. Median non-calcified plaque volumes increased from 27.5 mm 3 [interquartile range [IQR]: 10.1–55.5] to 53.5 mm 3 [24.0–97.9], with an annualized change of 4.9 mm 3 /year [1.4–9.6]. Calcified plaque volume increased from 0.3 mm 3 [0.0–5.7] to 3.2 mm 3 [0.1–18.2], with an annualized change of 0.4 mm 3 /year [0.0–2.4]. Low attenuation plaque (LAP) was present in 9% at baseline, and 23% at follow-up. Rapid plaque progression (annual percent atheroma volume (PAV) ≥ 1 % per PARADIGM) occurred in 6 participants (3 %), while 23 participants (11 %) exhibited an annual PAV increase ≥0.59 % (PARADIGM-derived intermediate threshold). Conclusion Over a median 5-year interval, atherosclerotic burden increased even in patients with minimal baseline CAC, no prior MACE, and no lipid-lowering therapy. Non-calcified plaque accumulated faster than calcified plaque. While rare in healthy individuals, LAP became more prevalent, and a small subset experienced rapid plaque progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI